Alentis Therapeutics Closes USD 105m Series C Funding
14. April 2023 – Walder Wyss advises Alentis Therapeutics in connection with their USD 105m Series C funding. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
The Walder Wyss team includes Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Associate, Corporate/M&A and Venture Capital), Lucas Maurer (Associate, Corporate/M&A and Venture Capital), Manuel Bigler (Managing Associate, IP/Licensing) as well as Katja Schott-Morgenroth (Partner, notarial services).